Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/20722
Title: Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction
Author: Giralt Torroella, Albert
Carreton, Olga
Lao-Peregrin, Cristina
Martin, Eduardo D.
Alberch i Vié, Jordi
Keywords: Corea de Huntington
Malalties del sistema nerviós
Patologia
Huntington's chorea
Nervous System Diseases
Pathology
Issue Date: 2011
Publisher: BioMed Central
Abstract: Background Brain-Derived Neurotrophic Factor (BDNF) is the main candidate for neuroprotective therapy for Huntington's disease (HD), but its conditional administration is one of its most challenging problems. Results Here we used transgenic mice that over-express BDNF under the control of the Glial Fibrillary Acidic Protein (GFAP) promoter (pGFAP-BDNF mice) to test whether up-regulation and release of BDNF, dependent on astrogliosis, could be protective in HD. Thus, we cross-mated pGFAP-BDNF mice with R6/2 mice to generate a double-mutant mouse with mutant huntingtin protein and with a conditional over-expression of BDNF, only under pathological conditions. In these R6/2:pGFAP-BDNF animals, the decrease in striatal BDNF levels induced by mutant huntingtin was prevented in comparison to R6/2 animals at 12 weeks of age. The recovery of the neurotrophin levels in R6/2:pGFAP-BDNF mice correlated with an improvement in several motor coordination tasks and with a significant delay in anxiety and clasping alterations. Therefore, we next examined a possible improvement in cortico-striatal connectivity in R62:pGFAP-BDNF mice. Interestingly, we found that the over-expression of BDNF prevented the decrease of cortico-striatal presynaptic (VGLUT1) and postsynaptic (PSD-95) markers in the R6/2:pGFAP-BDNF striatum. Electrophysiological studies also showed that basal synaptic transmission and synaptic fatigue both improved in R6/2:pGAP-BDNF mice. Conclusions These results indicate that the conditional administration of BDNF under the GFAP promoter could become a therapeutic strategy for HD due to its positive effects on synaptic plasticity.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/1750-1326-6-71
It is part of: Molecular Neurodegeneration, 2011, 6:71
Related resource: http://dx.doi.org/10.1186/1750-1326-6-71
URI: http://hdl.handle.net/2445/20722
ISSN: 1750-1326
Appears in Collections:Articles publicats en revistes (Biomedicina)

Files in This Item:
File Description SizeFormat 
1750-1326-6-71.pdf7.86 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons